JAMA
EMBARGOED FOR RELEASE: 6:35 A.M. ET, FRIDAY, JUNE 5, 2026
Media advisory: The full study is linked to this news release. This study is being presented at the 63rd European Renal Association Congress.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9923?guestAccessKey=45ba1cd9-3280-445f-878c-1e1585df3fee&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060526
About The Study: In this exploratory analysis, treatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist, slowed kidney function decline, reduced albuminuria, and lowered the risk of kidney failure or substantial loss of kidney function in patients with glomerular diseases. These findings suggest an important role for finerenone in preserving kidney function in this population.
Corresponding Author: To contact the corresponding author, Brendon L. Neuen, MBBS, MSc, PhD, email bneuen@georgeinstitute.org.au.
(doi:10.1001/jama.2026.9923)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.